The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.

Trial Profile

The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2015

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Thrombosis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 13 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top